SCHEMBL23540776

SCHEMBL23540776

CN(C(=O)OC(C)(C)C)c1c(N)cccc1Br

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 2/20 0.37
BRD4 O60885 2/20 0.36
PAX8 Q06710 1/20 0.36
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
HTT P42858 1/20 0.35
RAB9A P51151 1/20 0.35
KMT2A Q03164 1/20 0.35
NPSR1 Q6W5P4 1/20 0.33
CREBBP Q92793 1/20 0.33
SSTR4 P31391 1/20 0.33
AKT1 P31749 1/20 0.32
CTSS P25774 1/20 0.32
CTSK P43235 1/20 0.32
NCEH1 Q6PIU2 2/20 0.31
UCHL1 P09936 1/20 0.31
PKM P14618 1/20 0.31
ALDH1A1 P00352 1/20 0.30
HSD17B10 Q99714 1/20 0.30
MMP13 P45452 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30026361 1.00 AAK1 (0.37) AAK1BRD4PAX8MEN1NPC1
SCHEMBL30936643 0.84 BRD4 (0.37) AAK1BRD4PAX8MEN1HTT
SCHEMBL30936694 0.82 BRD4 (0.36) AAK1BRD4PAX8CREBBPCTSS
SCHEMBL30936586 0.82 BRD4 (0.36) BRD4PAX8MEN1KMT2ACREBBP
SCHEMBL23054111 0.82 ALDH1A1 (0.38) AAK1BRD4PAX8MEN1NPC1
SCHEMBL30893303 0.78 NPSR1 (0.38) PAX8HTTNPSR1ALDH1A1
SCHEMBL23540991 0.78 NPSR1 (0.38) PAX8HTTNPSR1ALDH1A1
SCHEMBL30893277 0.77 AAK1 (0.38) AAK1BRD4PAX8SSTR4
SCHEMBL4614237 0.76 HTR2C (0.37) AAK1MEN1NPC1HTTRAB9A
SCHEMBL13311040 0.75 PAX8 (0.41) AAK1BRD4PAX8MEN1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240383886-A1 Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof ABBVIE INC. 2024-11-21 US disclosed
CN-116194453-A Protein tyrosine phosphatase degrading agent and method of use thereof 卡里科生命科学有限责任公司 2023-05-30 CN disclosed
EP-4077319-A1 PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF Calico Life Sciences LLC (US) 2022-10-26 EP disclosed
WO-2021127586-A1 PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF CALICO LIFE SCIENCES LLC (US) 2021-06-24 WO disclosed
WO-2021127586-A1 PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF CALICO LIFE SCIENCES LLC (US) 2021-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383886-A1 Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof PTPN5, PTPN1, PTPN2 AAK1 708/4885BRD4 2745/4885PAX8 3335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.